ESMO Congress 2019
![Presidential symposium_ESMO 2019|ESMO 2019](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/are-we-reaching-a-turning-point-in-metastatic-prostate-cancer/8734075-3-eng-GB/are-we-reaching-a-turning-point-in-metastatic-prostate-cancer_i770.jpg)
Are we reaching a turning point in metastatic prostate cancer?
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer
![ESMO 2019_General view](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/updated-results-from-the-beacon-trial-show-unprecedented-overall-survival-in-the-second-line-treatment-of-crc/8735524-3-eng-GB/updated-results-from-the-beacon-trial-show-unprecedented-overall-survival-in-the-second-line-treatment-of-crc_i770.jpg)
Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
![General session-ESMO 2019](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/off-label-therapies-what-is-their-future/8735593-3-eng-GB/off-label-therapies-what-is-their-future_i770.jpg)
Off-label therapies: what is their future?
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
![ESMO 2019](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/claridhy-trial-reports-a-small-improvement-in-progression-free-survival/8735800-3-eng-GB/claridhy-trial-reports-a-small-improvement-in-progression-free-survival_i770.jpg)
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
![Breast cancer_ESMO 2019|ESMO Congress 2019-Barcelona-main entrance](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/chemotherapy-plus-endocrine-therapy-increases-long-term-recurrence-free-survival-in-women-with-high-risk-hr-breast-cancer/8735938-3-eng-GB/chemotherapy-plus-endocrine-therapy-increases-long-term-recurrence-free-survival-in-women-with-high-risk-hr-breast-cancer_i770.jpg)
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
![Salazar_Heracles_B|](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/targeting-her2-amplifications-in-metastatic-colorectal-cancer-searching-for-the-most-active-combination-therapy/8735179-3-eng-GB/targeting-her2-amplifications-in-metastatic-colorectal-cancer-searching-for-the-most-active-combination-therapy_i770.jpg)
Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
![ESMO 2019](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/closing-the-clinician-patient-gap-with-patient-reported-outcomes/8735386-3-eng-GB/closing-the-clinician-patient-gap-with-patient-reported-outcomes_i770.jpg)
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care